Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT02038738

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Sponsor: Ochsner Health System

Conditions Apudoma Carcinoid Carcinoid Tumor Islet Cell Tumor Neuroendocrine Neuroendocrine Cancer Neuroendocrine Carcinoma Neuroendocrine Tumor

Interventions 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.

Updated 7 times since 2017 Last updated: Jan 16, 2014 Started: Mar 31, 2014 Primary completion: Mar 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Apudoma and Carcinoid, this trial is ongoing. The trial is conducted by Ochsner Health System and has accumulated 7 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Apr 2019 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Apr 2019 [monthly]

Not Yet Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ochsner Health System

Data source: Ochsner Health System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kenner, United States